Ventyx Biosciences, Inc. filings document the company’s transition from a Nasdaq-listed clinical-stage biopharmaceutical issuer to a wholly owned subsidiary of Eli Lilly and Company. The record includes Form 8-K disclosures for the completed merger, shareholder voting results, material agreements, compensation arrangements and reported financial results.
Later corporate-status filings include Form 25 disclosure for removal of Ventyx common stock from Nasdaq listing and Form 15 disclosure for termination of registration or suspension of Exchange Act reporting obligations. Earlier filings also cover capital-structure matters, governance, risk factors and clinical or regulatory disclosures tied to the company’s oral small-molecule drug-development programs.